Alumis Inc
ALMS
查看详细走势图
24.800USD
-1.520-5.78%
收盘 03/27, 16:00（美东）报价延迟15分钟
1.29B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.78%
5天
-1.04%
1月
-16.47%
6月
+512.35%
今年开始到现在
+154.10%
1年
+427.66%
查看详细走势图
TradingKey Alumis Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Alumis Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名82/391位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价39.40。中期看，股价处于上升通道。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Alumis Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Alumis Inc亮点
亮点风险
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
业绩增长期
公司处于发展阶段，最新年度总收入24.05M美元
利润高增长
公司净利润处于行业前列，最新年度总收入24.05M美元
估值低估
公司最新PE估值-8.67，处于3年历史低位
机构加仓
最新机构持股79.11M股，环比增加1.13%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值69.17K
分析师目标
根据
11
位分析师
强力买入
评级
39.400
目标均价
+70.78%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Alumis Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Alumis Inc简介
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
公司代码ALMS
公司Alumis Inc
CEOBabler (Martin)
网址https://www.alumis.com/
相关品种
